Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2021-11-26 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Loss of Share Certificates
Regulatory Filings Classification · 100% confidence The document is a letter addressed to stock exchanges regarding the intimation of loss of share certificate. It references a regulatory requirement (Regulation 39(3) of SEBI Listing Obligations) and is essentially a notification to the exchange about a lost share certificate. The document is short (1491 characters) and does not contain financial data, audit information, management discussion, or any report content. It is a regulatory announcement related to share certificates but does not fit into categories like share issue, director dealings, or capital updates. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-11-26 English
Pursuant to the Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find attached herewith ....
Regulatory Filings
2021-11-26 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is titled as a transcript of an 'Analyst/Investor Conference Call' for Q2 FY22, dated November 11, 2021. It contains detailed spoken content from company executives discussing quarterly financial results, business segment performance, growth rates, and operational details. The text includes direct speech and Q&A style format typical of earnings call transcripts. It references the quarter and half-year ended September 30, 2021, and discusses financial metrics such as revenue, EBITDA, profit, and EPS. This matches the definition of a Call Transcript (CT), which is a full text transcript of company conference calls like earnings calls with Q&A. The document length is substantial (15,000 characters), and it contains the full transcript, not just an announcement or summary. Therefore, the correct classification is CT with high confidence.
2021-11-18 English
Please find attached transcript of 'Analyst/ Investor Conference Call' organised on Thursday, 11th November, 2021 at 04:00 P.M. (IST), subsequent to the declaration of unaudited standalone ....
Call Transcript Classification · 100% confidence The document is titled as a transcript of an 'Analyst/Investor Conference Call' for Q2 FY22, dated November 11, 2021. It contains detailed spoken remarks by company executives discussing quarterly financial results, business segment performance, growth rates, and outlook. The text includes a Q&A style format typical of earnings call transcripts. It references the quarter and half-year ended September 30, 2021, and discusses financial metrics such as revenue, EBITDA, profit, and EPS. The document is lengthy (15,000 characters) and contains the full text of the call, not just an announcement or summary. Therefore, this document fits the definition of a Call Transcript (CT) rather than an Earnings Release (ER) or Interim Report (IR).
2021-11-18 English
Pursuant to the Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find attached herewith letter dated 17th November, 2021, ....
Regulatory Filings
2021-11-17 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the loss of share certificates, referencing Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It is an official notification about a specific event related to share certificates, not a financial report, management change, or earnings release. The document is short (1493 characters) and serves as an intimation or regulatory announcement. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-11-17 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.